Tumor-associated Proteolysis
Prof. Dr. Viktor Magdolen
Prof. Dr. rer. nat. Viktor Magdolen
Clinical Research Unit
Department of Gynecology and Obstetrics
Technical University of Munich
Ismaninger Str. 22
81675 München
Tel.: 089-4140-2493
Fax: 089-4140-7410
Mail: viktor magdolen@tum.de(link sends e-mail)
- Sabine Creutzburg (technician)
- Daniela Hellmann (technician)
- Elisabeth Schüren (technician)
- Anne Andrulat (MD student)
- Larissa Dettmar (MD student)
- Tom Schulze (MD student)
- Anna Kellner (MD student)
- Thirza Singer (MD student)
- Sonja Schäfer (MD student)
- Yulia Bauer (MD student)
- Isabel Vogel (MD student)
- Biochemistry and structure of tumor-associated serine proteases, their inhibitors and their receptors
- Recombinant expression in E. coli, purification and refolding
- Enzymatic characterization of tumor-associated proteases
- Synthetic und natural inhibitors
- Clinical relevance of biomarkers in solid tumors
- Establishment of quantitative PCR assays, immunohistochemistry and ELISAs
- Generation of antibodies
- Analyses focus on:
- Components of the urokinase system (uPA, PAI-1, uPAR und its splice variant uPAR-del4/5, plasmin(ogen) / angiostatin
- Kallikrein-related peptidases (KLK1-KLK15)
- GTPase Rab31
- Therapy-relevant genes and miRNAs
- Tumor biology of different biomarker
- Tumor biological role of Rab31 and members of the uPA system
- Modulation of the expression of selected KLK proteases in ovarian, breast and prostate cancer cells: analyses of the effects on proliferation, migration, adhesion, invasion and expression of other tumor relevant genes (keratin 7, keratin 19, moesin)
Collaborators with shared publications (since 2018)
- Julia Dorn (KH Agatharied Hausham, Germany)
- Thomas Luther, Matthias Kotzsch (Labor Ostsachsen/TU Dresden, Germany)
- Daniela Loessner (Monash University, Melbourne, Australia)
- Nathalie Beaufort (LMU Munich, Germany)
- Thomas Kryza, John Hooper (University of Queensland, Woolloongabba, Australia)
- Ferda Ari, Engin Ulukaya (Bursa Uludag University, Turkey)
- Rudi Napieralski, Olaf Wilhelm (Therawis Diagnostics, Munich)
- Margaritis Avgeris, Andreas Scorilas (University of Athens, Greece)
- Jon Harris, Judith Clements (Queensland University of Technology, Brisbane, Australia)
- Oliver Goldhardt, Timo Grimmer (TU Munich)
- Michaela Aubele, Axel Walch (Helmholtz Zentrum, Neuherberg, Germany)
- Peter Göttig, Hans Brandstetter (Universität Salzburg, Austria)
- Yves Courty (University of Tours, France)
- Oliver Schilling (University of Freiburg, Germany)
- Hans-Jürgen Mägert (Hochschule Anhalt, Köthen, Germany)
- Eleftherios Diamandis (University of Toronto, Canada)
- Dalila Darmoul, Chahrazade El Amri (Sorbonne University, Paris, France)
- Deutsche Forschungsgemeinschaft
- Wilhelm Sander-Stiftung
- Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie
- Bayerisch-Französisches Hochschulzentrum (BayFrance/CCUFB)
- Bayerisches Hochschulzentrum für Lateinamerika (BAYLAT)
- Deutscher Akademischer Austauschdienst (DAAD)
- Deutsche Krebshilfe
- Alexander von Humboldt-Stiftung
- Bayerische Forschungsstiftung
- EU Socrates / Erasmus / Madame Curie Training Site Programme
- Kommission für klinische Forschungsprojekte der TUM (KKF)
- Collaborations with pharma and biotechology companies (Therawis GmbH, Iffmedic GmbH, Spherotec GmbH, Wilex AG, American Diagnostica Inc.)
Seitz S, Dreyer T, Stange C, Steiger K, Bräuer R, Scheutz L, Multhoff G, Weichert W, Kiechle M, Magdolen V, Bronger H (2022) CXCL9 inhibits tumor growth and drives anti-PD-L1 therapy in ovarian cancer. Br J Cancer, in press.
Panoutsopoulou K, Dreyer T, Dorn J, Obermayr E, Mahner S, van Gorp T, Braicu I, Zeillinger R, Magdolen V, Avgeris M, Scorilas A (2021) tRNAGlyGCC-derived internal fragment (i-tRF-GlyGCC) in ovarian cancer treatment outcome and progression. Cancers (Basel) 14:24
Soelch S, Beaufort N, Loessner D, Kotzsch M, Reuning U, Luther T, Kirchner T, Magdolen V (2021) Rab31-dependent regulation of transforming growth factor ß expression in breast cancer cells. Mol Med 27:158
Candido JB, Maiques O, Boxberg M, Kast V, Peerani E, Tomás-Bort E, Weichert W, Sananes A, Papo N, Magdolen V, Sanz-Moreno V, Loessner D (2021) Kallikrein‐related peptidase 6 is associated with the tumour microenvironment of pancreatic ductal adenocarcinoma. Cancers (Basel) 13:3969
Dreyer TF, Kuhn S, StangeC, Heithorst N, Schilling D, Jelsmaa J, Sievert W, Seitz S, Stangl S, Hapfelmeier A, Noske A, Wege AK, Weichert W, Ruland J, Schmitt M, Dorn J, Kiechle M, Reuning U, Magdolen V, Multhoff G, Bronger H (2021) The chemokine CX3CL1 improves trastuzumab efficacy in HER2 low expressing cancer in vitro and in vivo. Cancer Immunol Res 9:779-89
Riedel M, Bronger H, Magdolen V, Dreyer T (2021) The prognostic and diagnostic potential of kallikrein-related peptidases in ovarian cancer. Exp Rev Mol Diag 21:535-45
Kryza T, Khan T, Lovell S, Harrington BS, Yin J, Porazinski S, Pajic M, Koistinen H, Rantala J, Dreyer T, Magdolen V, Reuning U, He Y, Tate E, Hooper JD (2021) Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1. Nature Chem Biol 17:776-83
Ari F, Napieralski R, Akgun O, Magdolen V, Ulukaya E (2021) Epigenetic modulators combination with chemotherapy in breast cancer cells. Cell Biochem Funct 39:571-83
Gong W, Zhu C, Liu Y, Muckenhuber A, Bronger H, Scorilas A, Kiechle M, Dorn J, Magdolen V, Dreyer T (2021) Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer. Am J Trans Res 13:1594-1606
Napieralski R, Schricker G, Auer G, Aubele M, Perkins J, Magdolen V, Ulm K, Hamann M, Walch A, Weichert W, Kiechle M, Wilhelm OG (2021) PITX2 DNA-methylation: predictive versus prognostic value for anthracycline-based chemotherapy in triple-negative breast cancer patients. Breast Care 16:523-531